ArticlePreventive medicine reports2025
Potential association between magnesium depletion score and hyperuricemia in American adults, a cross-sectional study based on NHANES 2003-2018.
Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The pathophysiological mechanisms underlying hyperuricemia necessitate the identification of contributing factors to better understand disease progression and develop effective therapies. This study aimed to investigate the association between Magnesium Depletion Score (MDS) and hyperuricemia. Methods: A cross-sectional study was sourced from the National Health and Nutrition Examination Survey 2003-2018. Hyperuricemia was defined by serum uric acid levels. MDS was calculated by incorporating factors affecting renal magnesium reabsorption.Weighted multivariable logistic regression was employed to assess the association between MDS and hyperuricemia, with sensitivity analyses to confirm robustness. Additionally, Restricted Cubic Spline (RCS) and Receiver Operating Characteristic (ROC) curve analyses were used to further elucidate the relationship. Results: Compared to the low MDS group (0-1), the odds ratios (OR) and 95 % confidence intervals (CI) for the middle MDS group (2) and high MDS group (3-5) were 1.76 (1.52-2.04), and 3.14(2.54-3.88), respectively. The RCS analysis illustrated a linear dose-response relationship between MDS and hyperuricemia. The ROC analysis demonstrated that MDS had an area under the curve of 0.720 (95 % CI, 0.717-0.721). Conclusions: This study highlights a strong association between MDS and hyperuricemia risk, emphasizing the importance of addressing magnesium deficiency in hyperuricemic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.